ArticleBiochemical genetics2026
Expression of PSTPIP1 in Renal Cell Carcinoma and Its Prognostic Value.
Article in Biochemical genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Renal clear cell carcinoma is the most common histological form of renal cancer, but targeted therapy is still lacking. PSTPIP1 is associated with multiple immune-related pathways and is higher expressed in tumors. Thus, the correlation of PSTPIP1 and ccRCC (clear cell renal cell carcinoma) was studied to evaluate the therapeutic potential of PSTPIP1 as a target for tackling ccRCC. The expression of PSTPIP1 mRNA in clear cell renal cell carcinoma (ccRCC) was analyzed using the Oncomine, TCGA, UALCAN, GSCA, and GEPIA databases and analysis tools. Immunohistochemistry (IHC) was utilized to detect PSTPIP1 protein in clinical samples, and the chi-square test, univariate analysis and multivariate analysis were utilized to verify the relationship between PSTPIP1 and ccRCC. Co-expressed genes and enriched pathways were obtained from the TCGA and GSEA (Gene Set Enrichment Analysis) database and analysis tool. A protein-protein interaction network was constructed to support mechanism analysis. PSTPIP1 expression was significantly elevated in ccRCC tissues compared with normal renal tissues. PSTPIP1 expression levels showed significant correlations with tumor size, TNM stage, and PD-L1 status. Overexpression of PSTPIP1 was closely associated with patient survival, with high PSTPIP1 expression serving as a prognostic factor for reduced overall survival in ccRCC patients. Our findings indicate that high expression of PSTPIP1 is a predictor of poor prognosis in ccRCC patients, suggesting this protein may represent a potential therapeutic target for ccRCC treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.